Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
(NASDAQ: NVCR) Delayed: 16.72 +0.50 (3.08%)
Previous Close $16.22    52 Week High $28.95 
Open $16.58    52 Week Low $5.95 
Day High $16.99    P/E N/A 
Day Low $16.13    EPS $0.00 
Volume 1,482,648       

(NASDAQ: ZLAB) Delayed: 25.81 +1.14 (4.62%)
Previous Close $24.67    52 Week High $ 
Open $25.25    52 Week Low $ 
Day High $26.07    P/E N/A 
Day Low $25.03    EPS $ 
Volume 673,110